JP2020530446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530446A5 JP2020530446A5 JP2020505383A JP2020505383A JP2020530446A5 JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5 JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020505383 A JP2020505383 A JP 2020505383A JP 2020530446 A5 JP2020530446 A5 JP 2020530446A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- optionally substituted
- compound according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211691A JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543307P | 2017-08-09 | 2017-08-09 | |
| US62/543,307 | 2017-08-09 | ||
| US201762553728P | 2017-09-01 | 2017-09-01 | |
| US62/553,728 | 2017-09-01 | ||
| US201762608504P | 2017-12-20 | 2017-12-20 | |
| US62/608,504 | 2017-12-20 | ||
| PCT/US2018/045868 WO2019032743A1 (en) | 2017-08-09 | 2018-08-08 | COMPOUNDS, COMPOSITIONS AND METHODS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Division JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530446A JP2020530446A (ja) | 2020-10-22 |
| JP2020530446A5 true JP2020530446A5 (enExample) | 2021-09-16 |
Family
ID=65272557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505383A Withdrawn JP2020530446A (ja) | 2017-08-09 | 2018-08-08 | 化合物、組成物、及び、方法 |
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211691A Withdrawn JP2023052166A (ja) | 2017-08-09 | 2022-12-28 | 化合物、組成物、及び、方法 |
| JP2024223976A Pending JP2025031810A (ja) | 2017-08-09 | 2024-12-19 | 化合物、組成物、及び、方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11236100B2 (enExample) |
| EP (1) | EP3665156A4 (enExample) |
| JP (3) | JP2020530446A (enExample) |
| KR (2) | KR20250017299A (enExample) |
| CN (3) | CN118239938A (enExample) |
| AU (3) | AU2018313850B2 (enExample) |
| CA (1) | CA3071024A1 (enExample) |
| CL (1) | CL2020000299A1 (enExample) |
| CO (1) | CO2020001220A2 (enExample) |
| CR (1) | CR20200054A (enExample) |
| IL (2) | IL272089B2 (enExample) |
| MA (1) | MA49858A (enExample) |
| MX (2) | MX2020001352A (enExample) |
| MY (1) | MY201438A (enExample) |
| PE (1) | PE20200834A1 (enExample) |
| PH (1) | PH12020550028B1 (enExample) |
| SA (1) | SA520411222B1 (enExample) |
| SG (1) | SG11202000532SA (enExample) |
| TW (1) | TW201920115A (enExample) |
| WO (1) | WO2019032743A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025883A2 (pt) * | 2017-06-07 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | compostos químicos como inibidores da via de atf4 |
| MA49858A (fr) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CA3080971A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP3723762A4 (en) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | STRESS INTEGRATED RESPONSE PATH INHIBITORS |
| BR112020023115A2 (pt) | 2018-06-05 | 2021-02-02 | Praxis Biotech LLC | inibidores da via integrada de resposta a tensão |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| MA54959A (fr) * | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| AU2020262153B2 (en) | 2019-04-23 | 2026-01-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| IL287379B2 (en) | 2019-04-23 | 2025-11-01 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| US20200347043A1 (en) * | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| US20230125481A1 (en) | 2020-01-28 | 2023-04-27 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EP4117780A1 (en) * | 2020-03-11 | 2023-01-18 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| PL4232154T3 (pl) | 2020-10-22 | 2025-02-24 | Evotec International Gmbh | Modulatory zintegrowanego szlaku odpowiedzi na stres |
| MX2023004677A (es) * | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| MX2023004870A (es) * | 2020-10-30 | 2023-05-11 | Calico Life Sciences Llc | Moduladores de la via integrada del estres. |
| CN116507608A (zh) * | 2020-11-20 | 2023-07-28 | 戴纳立制药公司 | 化合物、组合物和方法 |
| CN116323620A (zh) * | 2020-11-25 | 2023-06-23 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的芳香族桥环酰胺衍生物 |
| CR20230254A (es) | 2020-12-18 | 2023-07-26 | Denali Therapeutics Inc | Formas sólidas de un compuesto |
| KR20250028345A (ko) * | 2022-06-23 | 2025-02-28 | 데날리 테라퓨틱스 인크. | 진핵생물 개시 인자 2b의 조절제를 제조하는 공정 |
| EP4624458A1 (en) * | 2022-11-21 | 2025-10-01 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof |
| WO2025019827A1 (en) * | 2023-07-20 | 2025-01-23 | Denali Therapeutics Inc. | Formulation, solid dosage form, and methods |
| WO2025230528A1 (en) * | 2024-05-01 | 2025-11-06 | Calico Life Sciences Llc | Methods of treating amyotrophic lateral sclerosis |
| WO2026004939A1 (ja) * | 2024-06-28 | 2026-01-02 | キッセイ薬品工業株式会社 | ジ置換ビシクロ［１．１．１］ペンタン化合物 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| ES2221440T3 (es) | 1998-10-16 | 2004-12-16 | Daiichi Suntory Pharma Co Ltd | Derivados de acido aminofenoxiacetico como neuroprotectores. |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| AU2001249417A1 (en) | 2000-04-26 | 2001-11-07 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| CA2443108A1 (en) | 2001-04-03 | 2002-10-17 | Merck & Co. Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| CN101068794B (zh) | 2004-09-02 | 2012-12-19 | 沃泰克斯药物股份有限公司 | 可用作离子通道调控剂的喹唑啉 |
| WO2006125974A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| SG170767A1 (en) | 2005-12-23 | 2011-05-30 | Zealand Pharma As | Modified lysine-mimetic compounds |
| US20080221100A1 (en) | 2006-10-20 | 2008-09-11 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| JP5274553B2 (ja) | 2007-06-15 | 2013-08-28 | アクテリオン ファーマシューティカルズ リミテッド | ３−アミノ−６−（１−アミノ−エチル）−テトラヒドロピラン誘導体 |
| NZ593891A (en) | 2008-12-12 | 2013-05-31 | Actelion Pharmaceuticals Ltd | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| GEAP202213376A (en) | 2009-06-17 | 2022-02-25 | Vertex Pharmaceuticals Incorporated Us | Inhibitors of influenza viruses replication |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| CN103403002B (zh) | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| AU2012245387C1 (en) * | 2011-04-22 | 2016-05-05 | Signal Pharmaceuticals, Llc | Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
| EP2814321B1 (en) | 2012-02-14 | 2018-09-26 | Syngenta Participations AG | Nematicidal cis (hetero)arylcyclopropylcarboxamide derivatives |
| CN104837820A (zh) | 2012-10-02 | 2015-08-12 | 大日本住友制药株式会社 | 咪唑衍生物 |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2015038778A1 (en) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| LT3126352T (lt) * | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| WO2016044331A1 (en) | 2014-09-17 | 2016-03-24 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| NZ730728A (en) * | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| EP3233087B1 (en) | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| KR20170137725A (ko) | 2015-02-25 | 2017-12-13 | 윌리엄 마쉬 라이스 유니버시티 | 데스아세톡시투불리신 h 및 이의 유사체 |
| GB201506894D0 (en) | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CA2984848A1 (en) | 2015-05-05 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TWI844006B (zh) * | 2016-05-05 | 2024-06-01 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| US10851053B2 (en) | 2016-06-08 | 2020-12-01 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| KR20190015748A (ko) | 2016-06-08 | 2019-02-14 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Atf4 경로 억제제로서의 화학적 화합물 |
| TWI749024B (zh) * | 2016-07-06 | 2021-12-11 | 美商艾克奎斯特有限責任公司 | 化合物及其於降低尿酸位準之用途 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US10093664B2 (en) | 2016-12-08 | 2018-10-09 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| BR112019025883A2 (pt) * | 2017-06-07 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | compostos químicos como inibidores da via de atf4 |
| BR112020000122A2 (pt) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças |
| CA3068395A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| MA49858A (fr) | 2017-08-09 | 2021-04-28 | Denali Therapeutics Inc | Composés, compositions et procédés |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| WO2019054430A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| KR20200092332A (ko) | 2017-11-02 | 2020-08-03 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절제 |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN112218869A (zh) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CA3080971A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CA3080964A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP3723762A4 (en) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | STRESS INTEGRATED RESPONSE PATH INHIBITORS |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| EP3820843A1 (en) | 2018-07-09 | 2021-05-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54959A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20220016467A (ko) | 2019-04-30 | 2022-02-09 | 칼리코 라이프 사이언시스 엘엘씨 | 통합된 스트레스 경로의 조절인자로서 치환된 사이클로알킬 |
| US20200347043A1 (en) | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CR20230254A (es) | 2020-12-18 | 2023-07-26 | Denali Therapeutics Inc | Formas sólidas de un compuesto |
-
2018
- 2018-08-08 MA MA049858A patent/MA49858A/fr unknown
- 2018-08-08 CN CN202410187269.9A patent/CN118239938A/zh active Pending
- 2018-08-08 PH PH1/2020/550028A patent/PH12020550028B1/en unknown
- 2018-08-08 AU AU2018313850A patent/AU2018313850B2/en active Active
- 2018-08-08 CA CA3071024A patent/CA3071024A1/en active Pending
- 2018-08-08 CR CR20200054A patent/CR20200054A/es unknown
- 2018-08-08 SG SG11202000532SA patent/SG11202000532SA/en unknown
- 2018-08-08 KR KR1020257001611A patent/KR20250017299A/ko active Pending
- 2018-08-08 IL IL272089A patent/IL272089B2/en unknown
- 2018-08-08 EP EP18844666.0A patent/EP3665156A4/en active Pending
- 2018-08-08 PE PE2020000174A patent/PE20200834A1/es unknown
- 2018-08-08 IL IL301709A patent/IL301709B2/en unknown
- 2018-08-08 JP JP2020505383A patent/JP2020530446A/ja not_active Withdrawn
- 2018-08-08 WO PCT/US2018/045868 patent/WO2019032743A1/en not_active Ceased
- 2018-08-08 KR KR1020207005952A patent/KR102757890B1/ko active Active
- 2018-08-08 MX MX2020001352A patent/MX2020001352A/es unknown
- 2018-08-08 US US16/637,718 patent/US11236100B2/en active Active
- 2018-08-08 CN CN201880055607.6A patent/CN111094233B/zh active Active
- 2018-08-08 MY MYPI2020000561A patent/MY201438A/en unknown
- 2018-08-08 CN CN202410183135.XA patent/CN118239937A/zh active Pending
- 2018-08-09 TW TW107127864A patent/TW201920115A/zh unknown
-
2020
- 2020-01-31 MX MX2023003989A patent/MX2023003989A/es unknown
- 2020-02-02 SA SA520411222A patent/SA520411222B1/ar unknown
- 2020-02-03 CO CONC2020/0001220A patent/CO2020001220A2/es unknown
- 2020-02-03 CL CL2020000299A patent/CL2020000299A1/es unknown
-
2021
- 2021-11-19 US US17/531,039 patent/US11851440B2/en active Active
-
2022
- 2022-12-28 JP JP2022211691A patent/JP2023052166A/ja not_active Withdrawn
-
2023
- 2023-03-22 AU AU2023201775A patent/AU2023201775A1/en not_active Abandoned
-
2024
- 2024-12-19 JP JP2024223976A patent/JP2025031810A/ja active Pending
-
2025
- 2025-01-08 US US19/014,044 patent/US20250388595A1/en active Pending
- 2025-01-31 AU AU2025200658A patent/AU2025200658A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530446A5 (enExample) | ||
| US11795164B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| TWI724079B (zh) | 可溶性鳥苷酸環化酶刺激劑 | |
| JP2020532506A5 (enExample) | ||
| JP5728487B2 (ja) | 三環式ヘテロ環化合物 | |
| US20100280082A1 (en) | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | |
| US11254663B2 (en) | Substituted bicyclic compounds as farnesoid X receptor modulators | |
| JP2017193592A5 (enExample) | ||
| JP5602230B2 (ja) | スフィンゴシン−１−リン酸受容体アゴニスト | |
| JP5973576B2 (ja) | Ｐｄｅ１０モジュレーター | |
| JP2009525340A5 (enExample) | ||
| WO2013192125A1 (en) | Pyrazolyl derivatives as syk inhibitors | |
| JP2018529745A (ja) | Ｎｒｆ２レギュレーターとしてのビアリールピラゾール | |
| JP2017523223A5 (enExample) | ||
| JP2020520925A5 (enExample) | ||
| KR20210032936A (ko) | Il-17 및 ror감마의 저해를 위한 피라졸 및 이미다졸 화합물 | |
| JPWO2020047312A5 (enExample) | ||
| JPWO2020002950A5 (enExample) | ||
| WO2015155566A1 (en) | Fused pyrazole compounds as cb1r antagonists and uses thereof | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 | |
| JPWO2023053015A5 (enExample) | ||
| JPWO2021191838A5 (enExample) | ||
| HK1255028B (en) | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases |